Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 15 to 23 amino acid residues in defined sequence
Reexamination Certificate
2004-09-10
2008-03-25
Tsang, Cecilia J. (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
15 to 23 amino acid residues in defined sequence
Reexamination Certificate
active
07348401
ABSTRACT:
The present invention relates to compositions, including pharmaceutical compositions that inhibit complement activation, and contain amino acid sequences X1-X2-X3-W-E-X4-X5-X6and/or Z1-C1-Z2-P-Z3-Z4-C2-Z5as described. The invention further relates to methods of inhibiting complement activation in vivo or ex vivo by administering a pharmaceutical composition as described herein.
REFERENCES:
patent: 4916219 (1990-04-01), Linhardt et al.
patent: 5661015 (1997-08-01), Binger et al.
patent: 6232296 (2001-05-01), Henry
patent: 6319897 (2001-11-01), Lambris et al.
patent: 6667173 (2003-12-01), Kazlauskas et al.
patent: 6703364 (2004-03-01), Kalafatis et al.
patent: WO 99/13899 (1999-03-01), None
Flynn, J.S., et al. “Vaccination with a Feline Immunodeficiency Virus Multiepitopic Peptide Induces Cell-Mediated and Humoral Immune Responses in Cats, but Does Not Confer Protection,” Journal of Virology (1997), vol. 71, pp. 7586-7592.
Johnson et al., “Development of Novel Inhibitors of Complement.”FASEB Journal, vol. 18, No. 4-5, pp. abstract 777.6, 2004.
Kapil et al., “Synthetic Peptide As Inhibitors of Human Complement Activation.”Protein and Peptide Letters, vol. 4, No. 6, pp. 405-408, 1997.
Adachi et al., “Effects of Cyclosporine, Aspirin, and Cobra Venom Factor on Discordant Cardiac Xenograft Survival in Rats.”Transplantation Proceedings, vol. XIX, No. 1, pp. 1145-1148, 1987.
Ahrehstedt et al., “Enhanced Local Production of Complement Components in the Small Intestines of Patients with Crohn's Disease.”The New England Journal of Medicine, vol. 322, No. 19, pp. 1345-1349, 1990.
Arumugam et al., “A Small Molecule C5a Receptor Antagonist Protects Kidneys from Ischemia/Reperfusion Injury in Rats.”Kidney International, vol. 63, pp. 134-142, 2003.
Barohn et al., “Soluble Terminal Complement Components in Human Myasthenia Gravis.”Clinical Neurology and Neurosurgery, vol. 95, pp. 285-290, 1993.
Beeley, N., “Peptidomimetics and Small-Molecule Drug Design: Towards Improved Bioavailability and In Vivo Stability.”Trends in Biotechnology, vol. 12, pp. 213-216, 1994.
Biesecker et al., “Inhibition of Acute Passive Transfer Experimental Autoimmune Myasthenia Gravis with Fab Antibody to Complement C61.”The Journal of Immunology, vol. 142, No. 8, pp. 2654-2659, 1989.
Blair et al., “Linkage of Cytotoxic Agents to Immunoglobulins.”Journal of Immunological Methods, vol. 59, pp. 129-143, 1983.
Bonfanti et al., “p21WAF1-derived Peptides Linked to an Internalization Peptide Inhibit Human Cancer Cell Growth1.”Cancer Research, vol. 57, pp. 1442-1446, 1997.
Bradt et al., “Complement-dependent Proinflammatory Properties of the Alzheimer's Disease β-Peptide.”The Journal of Experimental Medicine, vol. 188, No. 3, pp. 431-438, 1998.
Broughton et al., “Radioimmunoassay of Antibiotics and Chemotherapeutic Agents.”Clinical Chemistry, vol. 22, No. 6, pp. 726-732, 1976.
Butler, V., “Drug Immunoassays.”Journal of Immunological Methods, vol. 7, pp. 1-24, 1975.
Chenoweth, D., “Anaphylatoxin Formation in Extracorporeal Circuits.”Complement Inflammation, vol. 3, pp. 152-165, 1986.
Cochrane, C., “The Role of Complement in Experimental Disease Models.”Springer Seminars in Immunopathology, vol. 7, pp. 263-270, 1984.
Couser et al., “Complement and the Direct Mediation of Immune Glomerular Injury: A New Perspective.”Kidney International, vol. 28, pp. 879-890, 1985.
Crestfield et al., “The Preparation and Enzymatic Hydrolysis of Reduced and S-Carboxymethylated Proteins.”The Journal of Biological Chemistry, vol. 238, No. 2, pp. 622-627, 1963.
Cunningham et al., “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis.”Science Reports, vol. 244, pp. 1081-1085, 1989.
Demling et al., “The Lung Inflammatory Response to Thermal Injury: Relationship Between Physiological and Histologic Changes.”Surgery, vol. 52-59, vol. 106, No. 1, 1988.
Deppisch et al., “Fluid Phase Generation of Terminal Complement Complex as a Novel Index of Bioincompatibility.”Kidney International, vol. 37, pp. 696-706, 1990.
Erlanger, B., “The Preparation of Antigenic Hapten-Carrier Conjugates: A Survey.”Methods in Enzymology, vol. 70, pp. 85-104, 1980.
Fava et al., “Critical Role of Peripheral Blood Phagocytes and the Involvement of Complement in Tumour Necrosis Factor Enhancement of Passive Collagen-Arthritis.”Clin. Exp. Immunol,vol. 94, pp. 261-266, 1993.
Feasby et al., “Complement Depletion Suppresses Lewis Rat Experimental Allergic Neuritis.”Brain Research, vol. 419, pp. 97-103, 1987.
Gallinaro et al., “The Role of the Complement System in Trauma and Infection.”Surgery, Gynecology and Obstetrics, vol. 174, pp. 435-440, 1992.
Gauthier et al., “Effect of Cationized Antibodies in Preformed Immune Complexes on Deposition and Persistence in Renal Glomeruli.”Journal of Experimental Medicine, vol. 156, pp. 766-777, 1982.
Gelfand et al., “Alternative Complement Pathway Activation Increases Mortality in a Model of Burn Injury in Mice.”Journal of Clinical Investigation, vol. 70, pp. 1170-1176, 1982.
Guttmann, D., “Genetics of Acute Rejection of Rat Cardiac Allografts and a Model of Hyperacute Rejection.”Transplantation,vol. 17, No. 4, pp. 383-386, 1974.
Hack et al., “Elevated Plasma Levels of the Anaphylatoxins C3a and C4a are Associated with a Fatal Outcome in Sepsis.”The American Journal of Medicine, vol. 86, pp. 20-26, 1989.
Hruby, V., “Conformational and Topographical Considerations in the Design of Biologically Active Peptides.”Biopolymers, vol. 33, pp. 1073-1082, 1993.
Jones et al., “Expression of Complement Regulatory Molecules and Other Surface Markers on Neutrophils from Synovial Fluid and Blood of Patients with Rheumatoid Arthritis.”British Journal of Rheumatology, vol. 33, pp. 707-712, 1994.
Kilgore et al., “The Complement System in Myocardial Ischaemia/Reperfusion Injury.”Cardiovascular Research, vol. 28, pp. 437-444, 1994.
Knechtle et al., “The Effect of Cyclosporine, Total Lymphoid Irradiation, and Cobra Venom Factor on Hyperacute Rejection.”Heart Transplantation and Immunology, vol. IV, No. 5, pp. 541-545, 1985.
Kojima et al., “Activation of Complement of Hemodialysis Membrane.”Nippon Jenzo Gakkai Shi, vol. 31, pp. 91-97, 1989.
Kulkarni et al., “Covalent Binding of Methotrexate to Immunoglobulins and the Effect of Antibody—linked Drug on Tumor Growth in Vivo1.”Cancer Research, vol. 41, pp. 2700-2706, 1981.
Kyte et al., “A Simple Method for Displaying the Hydropathic Character of a Protein.”Journal of Molecular Biology, vol. 157, pp. 105-132, 1982.
Langlois et al., “Accentuated Complement Activation in Patient Plasma During the Adult Respiratory Distress Syndrome: A Potential Mechanism for Pulmonary Inflammation.”Heart and Lung, vol. 18, pp. No. 1, pp. 71-84, 1989.
Lennon et al., “Role of Complement in the Pathogenesis of Experimental Autoimmune Myasthenia Gravis.”Journal of Experimental Medicine, vol. 147, pp. 973-983, 1977.
Leventhal et al., “Prolongation of Cardiac Xenograft Survival by Depletion of Complement.”Transplantation, vol. 55, No. 4, pp. 857-866, 1993.
Liszewski et al., “Control of the Complement System.”Advances in Immunology, vol. 61, pp. 201-283, 1996.
Makrides, S., “Therapeutic Inhibition of the Complement System.”Pharmacological Reviews, vol. 50, No. 1, pp. 59-87, 1989.
Matsushita, M., “The Lectin Pathway of the Complement System.”Microbiology Immunology, vol. 40, pp. 887-893, 1996.
McClean, R., “Complement and Glomerulonephritis—An Update.”Pediatric Nephrology, vol. 7, pp. 226-232, 1993.
Moll
Johnson Richard J.
Maves Shelley A.
Heard Thomas S.
Innate Biotech, Inc.
Senniger Powers
Tsang Cecilia J.
LandOfFree
Peptides that inhibit complement activation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides that inhibit complement activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides that inhibit complement activation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3977214